Breast Cancer Liquid Biopsy Market Development & Future Trends
Seeking Alpha Analyst Since 2014
#Healthcare Consultant focusing on #TeleHealth #TeleMedicine #PatientPortals #CVIS #HCIT #MedicalRobots #Vaccines #MedicalDevices #WirelessHealth #Biotechnology
Summary
- Which are the Market Growth Factors?
- Top Segments & Global market size.
- Leading players in the global breast cancer liquid biopsy market.
Market growth influenced due to following factors-
- Increasing preference for non-invasive procedures.
- Initiatives undertaken by government and global health organizations.
- Technological advancement to augment market revenues.
- Rising emphasis on personalized medicine.
Global market size-
According to the new market research report Breast Cancer Liquid Biopsy Market is expected to reach $ 411.1 million by 2022, at a CAGR of 23.1%..
Top Segment -
•Based on circulating biomarkers, the market is categorized into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vehicles (EVs), and other circulating biomarkers. In 2017, the cfDNA segment is expected to account for the largest share of the breast cancer liquid biopsy market.
•Based on end user, the breast cancer liquid biopsy market is segmented into reference laboratories, hospitals and physician laboratories, and other end users (research institutes, public health laboratories, pathology laboratories, and small molecular laboratories).
For Details, Download PDF Brochure Here
Top players & growth strategies –
The key players in the global breast cancer liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.